TDSGF (Telo Genomics) YoY EBITDA Growth: 33.33% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Telo Genomics YoY EBITDA Growth?

Telo Genomics TDSGF YoY EBITDA Growth is 33.33% as of Mar. 2026. The stock has 2 warning signs investors should review.

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Telo Genomics's YoY EBITDA Growth for the quarter that ended in Mar. 2026 was 33.33%.

Telo Genomics's EBITDA per Share for the three months ended in Mar. 2026 was $-0.00.

Telo Genomics YoY EBITDA Growth Historical Data

* Premium members only.

The historical data trend for Telo Genomics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Telo Genomics YoY EBITDA Growth Chart

Telo Genomics Annual Data
Trend Dec15 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.00 -28.57 -29.63 22.86 18.52

Telo Genomics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 16.67 20.00 33.33 33.33

Telo Genomics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Telo Genomics's YoY EBITDA Growth for the fiscal year that ended in Jun. 2025 is calculated as:

YoY EBITDA Growth (A: Jun. 2025 )
=(EBITDA per Share (A: Jun. 2025 )-EBITDA per Share (A: Jun. 2024 ))/ | EBITDA per Share (A: Jun. 2024 ) |
=(-0.022--0.027)/ | -0.027 |
=18.52 %

Telo Genomics's YoY EBITDA Growth for the quarter that ended in Mar. 2026 is calculated as:

YoY EBITDA Growth (Q: Mar. 2026 )
=(EBITDA per Share (Q: Mar. 2026 )-EBITDA per Share (Q: Mar. 2025 )) / | EBITDA per Share (Q: Mar. 2025 )) |
=(-0.004--0.006)/ | -0.006 |
=33.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EBITDA Growth →
What does a YoY EBITDA Growth of 33.33% mean?
Telo Genomics (TDSGF) has a YoY EBITDA Growth of 33.33% as of Mar. 2026. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Telo Genomics and its competitors.
Is Telo Genomics' YoY EBITDA Growth too high?
Telo Genomics' current YoY EBITDA Growth is 33.33%.
How does Telo Genomics' YoY EBITDA Growth compare to TMO and DHR?
Telo Genomics' YoY EBITDA Growth of 33.33% can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EBITDA Growth for a Medical Diagnostics & Research company?
A good YoY EBITDA Growth depends on the Medical Diagnostics & Research industry context. However, YoY EBITDA Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EBITDA Growth mean?
A high YoY EBITDA Growth can signal that a stock is expensive relative to its fundamentals. YoY EBITDA Growth is the percentage change of EBITDA per share over the past 12-month. View historical data for Telo Genomics and its competitors. Telo Genomics's current YoY EBITDA Growth is 33.33%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Telo Genomics stock overvalued right now?
Telo Genomics (TDSGF) has a current YoY EBITDA Growth of 33.33%. The current YoY EBITDA Growth is 33.33%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EBITDA Growth calculated?
YoY EBITDA Growth is calculated from a company's financial statements. For Telo Genomics (TDSGF), the current YoY EBITDA Growth is 33.33% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Telo Genomics Business Description

Other Exchanges 3D0A:GermanyTELO:Canada
Address 2255 York Avenue, Suite 203, Vancouver, BC, CAN, V6K 1C5
Telo Genomics Corp is a personalized medicine company. The company through its wholly-owned subsidiary is engaged in developing diagnostic and prognostic products that may save lives, improve the quality of life, and reduce the cost of care associated with numerous diseases that display genomic instability. The company has a single operating segment, focused on the development and commercialization of predictive technological products designed to personalize treatment plans for patients who have specific conditions.